Department of Cardiovascular Medicine, Graduate School of Medical Sciences.
Circ Cardiovasc Interv. 2013 Aug;6(4):452-9. doi: 10.1161/CIRCINTERVENTIONS.112.000278. Epub 2013 Aug 6.
Dual antiplatelet therapy with aspirin and clopidogrel is widely used in patients with coronary stents. High residual platelet reactivity (high RPR) after dual antiplatelet therapy is associated with increased cardiovascular events. Endothelial function could affect platelet reactivity in vivo. We hypothesized that endothelial dysfunction could be associated with high RPR after dual antiplatelet therapy in patients with stable coronary artery disease.
We screened patients with stable coronary artery disease for cytochrome P450 (CYP) 2C19 genotypes and enrolled 103 patients who lacked CYP2C19*2 or *3 loss-of-function allele to minimize the effect of this gene on high RPR. All patients received aspirin (100 mg/d) and clopidogrel (75 mg/d for long-term treatment or a loading dose of 300 mg) before the following tests. Platelet aggregability was assessed as P2Y12 reaction unit using the VerifyNow System. High RPR was defined as P2Y12 reaction unit ≥ 230. Peripheral endothelial function was expressed as reactive hyperemia index using reactive hyperemia peripheral arterial tonometry. Fifty-three patients exhibited high RPR. High RPR patients were significantly older, had higher levels of B-type natriuretic peptide, and were predominantly hypertensive compared with non-high RPR patients. Reactive hyperemia index was significantly lower in high RPR patients (0.46 ± 0.15) compared with non-high RPR patients (0.61 ± 0.18; P<0.001). Linear regression analysis demonstrated significant negative correlation between reactive hyperemia index and P2Y12 reaction unit (r=-0.32; P=0.001). Multivariable logistic regression analysis identified reactive hyperemia index as an independent and significant determinant of high RPR (odds ratio, 0.55; 95% confidence interval, 0.39-0.78; P=0.001).
In patients with stable coronary artery disease, endothelial function was significantly impaired in high RPR patients. Endothelial dysfunction is independently correlated with high RPR after dual antiplatelet therapy.
http://www.umin.ac.jp/ctr. Unique identifier: UMIN000008239.
阿司匹林和氯吡格雷双联抗血小板治疗广泛应用于冠脉支架术后患者。双联抗血小板治疗后高残余血小板反应性(high RPR)与心血管事件增加相关。内皮功能可能会影响体内血小板反应性。我们假设,在稳定型冠心病患者中,内皮功能障碍可能与双联抗血小板治疗后高 RPR 相关。
我们对稳定型冠心病患者进行细胞色素 P450(CYP)2C19 基因型筛查,并纳入 103 例无 CYP2C192 或3 失活等位基因的患者,以最大限度减少该基因对高 RPR 的影响。所有患者在以下检查前均接受阿司匹林(100mg/d)和氯吡格雷(长期治疗时 75mg/d 或负荷剂量 300mg)。使用 VerifyNow 系统评估血小板聚集率作为 P2Y12 反应单位。高 RPR 定义为 P2Y12 反应单位≥230。使用反应性充血外周动脉张力测定法表示外周内皮功能作为反应性充血指数。53 例患者表现为高 RPR。与非高 RPR 患者相比,高 RPR 患者年龄较大,B 型利钠肽水平较高,且以高血压为主。高 RPR 患者的反应性充血指数明显低于非高 RPR 患者(0.46±0.15 比 0.61±0.18;P<0.001)。线性回归分析显示,反应性充血指数与 P2Y12 反应单位呈显著负相关(r=-0.32;P=0.001)。多变量 logistic 回归分析表明,反应性充血指数是高 RPR 的独立显著决定因素(比值比,0.55;95%置信区间,0.39-0.78;P=0.001)。
在稳定型冠心病患者中,高 RPR 患者的内皮功能明显受损。内皮功能障碍与双联抗血小板治疗后高 RPR 独立相关。
http://www.umin.ac.jp/ctr. 唯一标识符:UMIN000008239.